Two molecules that affected the cell cycle only of acute myeloid leukemia (AML) cells could be used as a clinical strategy against this pathology. Scientists at Memorial Sloan Kettering Cancer Center and Harvard University have discovered that DEG-35 and DEG-77 arrested the cell cycle and promoted cell differentiation and apoptosis in these cells.
Janssen Pharmaceutica NV and Johnson & Johnson (China) Investment Ltd. have identified substituted phenyl-1H-pyrrolo [2, 3-c] pyridine derivatives acting as menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer.
Ordaōs Bio Inc. has entered into a joint development agreement with Yatiri Bio Inc. to create new therapeutics for two novel targets in acute myeloid leukemia (AML).
The histone-lysine N-methyltransferase 2A (KMT2A; also known as mixed-lineage leukemia 1 [MLL1])-fusion proteins require direct interaction with the nuclear scaffolding protein menin in order to form menin-KMT2A complex, which plays a key role in the transcription of multiple leukemogenic target genes. On the basis of this, it is hypothesized that blocking the menin-KMT2A interaction by small-molecule inhibitors could be a promising new strategy for the treatment of KMT2A-altered and NPM1-mutant acute myeloid leukemia (AML).
Umoja Biopharma Inc. and Nanjing Iaso Biotherapeutics Co. Ltd. have entered into a research agreement to evaluate Umoja's ICIL (induced cytotoxic innate lymphocytes) platform with Iaso's best-in-class chimeric antigen receptors (CARs).
Eterna Therapeutics Inc. has entered into a sponsored research agreement with a collaborator at The University of Texas MD Anderson Cancer Center (MD Anderson).
In relapsed/refractory acute myeloid leukemia (AML), an indication that still needs adequate standard-of-care therapy, Actinium Pharmaceuticals Inc.’s topline pivotal phase III data shone brightly with radiotherapy lead candidate Iomab-B.
